FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
Lawsuit Does Not Cite Overlap In Companies’ Portfolios
Executive Summary
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
You may also be interested in...
Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.
Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business
US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira.